Cargando…
Adjuvant trastuzumab: progress, controversies, and the steps ahead
The major breast cancer story of 2005 was trastuzumab, a monoclonal antibody directed against the Her-2 oncoprotein, and how it greatly improves outcomes for women with HER2-positive early-stage breast cancer. With early results showing that use of the drug can prevent roughly one half of relapses,...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Multimed Inc.
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891169/ https://www.ncbi.nlm.nih.gov/pubmed/17576436 |